RA TV Episode 3

AUGUST 26, 2020
Peter Kolchinsky, PhD, and members of the RA Capital Covid-19 Team
What data did human convalescent serum show for approval, and what does this mean for companies developing antibodies; What would accelerated approval for a vaccine mean for opening up the country, and the development of other vaccines; Possibilities of reinfection.

Sign up to access our Covid-19 discussions:

We offer periodic Zoom discussions with members of the RA Capital team on recent scientific developments related to Covid-19. We welcome participation from members of industry, government, media, academia, medicine, NGOs, and more. Please see our Covid-19 page for information regarding upcoming live discussions. All discussions are also recorded and posted to our library.

Please enter your email address to receive access to RA Capital's past and future Covid-19 discussions.

Our website handles your ongoing access to our Covid-19 Discussions via a browser cookie. If you delete your cookies or use a different browser, you will need to re-enter your email address to regain access. perspectives@racap.com if you should need technical assistance.

This system will not work with an old Internet Explorer browser. Chrome, Safari, and Internet Explorer 11 or later are all currently compatible.

Disclaimer:

RA Capital Management, LP (“RA Capital”) is an investment adviser registered with the Securities and Exchange Commission (“SEC”) under the Investment Advisers Act of 1940, as amended (“Advisers Act”).
From time to time, RA Capital may hold long and/or short positions in companies which are mentioned in or are contributors to this presentation. Furthermore, RA Capital may provide support to other entities which may contribute (for example, No Patient Left Behind). This presentation is for informational purposes only, and is not intended as investment advice, nor is it an inducement or offer of any product or service offered by RA Capital. Discussion of any companies (public or private) is for illustrative purposes only and should not be taken as a recommendation to buy, sell, or hold any security. Similarly, all views expressed regarding other factors, including potential legislative actions and their effect on markets, is current as of the date of the webinar and is subject to change without notice. Nothing in this presentation should be considered medical advice or guidance.